Resource use and costs of exenatide bid or insulin in clinical practice: the European CHOICE study

Keyphrases

• Clinical Practice 100%
• Insulin 100%
• Resource Use 100%
• Exenatide 100%
• Resource Cost 100%
• Injectable Therapies 37%
• Mean Cost 37%
• Insulin Therapy 25%
• Direct Costs 25%
• Type 2 Diabetic Patients 12%
• Glycemic Control 12%
• European Countries 12%
• Clinical Application 12%
• Patient Characteristics 12%
• Disease Pattern 12%
• Non-interventional 12%
• Insulin Initiation 12%
• Cost Implications 12%
• National Health System 12%
• Bid Initiation 12%
• Systems Perspective 12%
• Health Service Utilization 12%
• Cost Difference 12%
• Across Countries 12%
• Healthcare Costs 12%
• Treatment Change 12%
• Patient Healthcare 12%
• Data Use 12%

Nursing and Health Professions

• Clinical Practice 100%
• Exendin 4 100%
• Insulin 100%
• Insulin Treatment 25%
• Health Care Cost 12%
• Patient with Type 2 Diabetes 12%
• Healthcare System 12%
• Health Care Utilization 12%
• Public Health Service 12%
• Diseases 12%
• Glycemic Control 12%

Pharmacology, Toxicology and Pharmaceutical Science

• Exendin 4 100%
• Insulin 100%
• Observational Study 12%
• Diseases 12%
• Maturity Onset Diabetes of the Young 12%